Weight-Loss Spending at Med Spas Flattened in 2025

Patients spent $2.2 billion on weight loss at U.S. medical aesthetics practices in 2025, roughly the same as the year before. It is the first full year without double- or triple-digit growth for the category since GLP-1 drugs arrived in 2021, and it changes the math for any owner deciding whether to add or keep a weight-loss line. [1]

What the data shows

Guidepoint Qsight, which tracks transactions across thousands of U.S. aesthetic practices, puts 2025 patient spending on weight loss and dietary lifestyle treatments at $2.2 billion, roughly level with 2024. The broader aesthetics market still grew about 4% year over year, so the plateau is specific to weight loss. [1]

The arc inside the year is steeper than the annual figure suggests. Analysis of Qsight's quarterly data shows category spending peaking in the first quarter of 2025, then falling in each of the next three quarters to $493 million in the fourth. Quarterly spending is still roughly ten times what it was in early 2021, but the direction has flipped. [1][4]

The longer run tells the same story: category growth of 74% in 2022, 235% in 2023 and 55% in 2024, then a flat 2025. [2]

Retention is the counterweight. From 2024 to 2025, 46% of medical aesthetics patients returned for more weight-loss treatments, the second-highest retention of any category in the data, behind neurotoxins at 57%. [1][4]

Why growth stopped

The category's hypergrowth ran on the GLP-1 shortage era. While semaglutide and tirzepatide sat on FDA's shortage list, compounders had a legal route to supply them, and the Skytale report says compounded GLP-1 drugs "account for most of the sales in this category" at aesthetic practices. [2]

That route has narrowed. FDA determined the tirzepatide injection shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025. The grace periods FDA gave compounders were time-limited: the last dated window, covering semaglutide outsourcing facilities, ran to May 22, 2025 or a district court decision in pending litigation, whichever came later. FDA has also proposed excluding semaglutide, tirzepatide and liraglutide from the bulk substances outsourcing facilities may use, saying it found no clinical need; we found no final determination in a Federal Register search as of November 2, 2026, and the proposal applies to 503B outsourcing facilities, not 503A pharmacies. [4][6]

The same reporting flags ongoing legal activity and new strategic pricing decisions from name-brand manufacturers as reasons the segment remains one to watch. [2]

Who is still in the business

Adoption remains wide. As of August 2025, 54% of med spas and 32% of plastic surgery clinics offered GLP-1 therapies, according to Qsight's market report, and the drugs made up 12% of monthly revenue at practices offering them as of 2024. [3]

What has changed is the posture required. With category-level growth gone, a weight-loss line competes on retention, operations and compliant supply rather than on rising demand. Qsight describes the current moment as a recalibration period that rewards practices able to reposition treatments and set realistic expectations. [1]

The rules are catching up

The operating model is being regulated directly as well. Maine's Chapter 15 joint rule, adopted by the state's medical, nursing and osteopathic boards and effective July 14, 2026, defines a "medical aesthetic business" to include medical weight loss treatment, and sets standards for clinical assessment and the licensee-patient relationship: [5]

• A "simple questionnaire" without an appropriate clinical assessment does not meet the standard of care for issuing prescriptions.
• Being an owner, investor or designated medical director of the business is "insufficient to establish a valid licensee-patient relationship."
• Standing orders used for individualized assessment, diagnosis and treatment are "considered unprofessional conduct and may result in disciplinary action."

Maine is one state, and other states differ. But its rule shows what boards can demand of a remote-prescriber weight-loss model: a real examination relationship, prescriptions tied to individual assessment, and documented records. [4][5]

The category is not shrinking. It is normalizing, and a normalized category rewards operators, not early movers.

What it means for a clinic: If a weight-loss line only worked while demand grew 50% a year, it no longer works on autopilot. The plateau moves the business case to retention, pricing discipline and compliant sourcing. Three checks follow: whether your weight-loss patients return at least at the category's 46% rate, whether your prescriber arrangements would survive a rule like Maine's, and whether every supplier sits cleanly inside the post-shortage compounding rules. From here, growth in this line comes from taking share, not from the tide.